Ben Burnett (Wells Fargo)

Focus Areas3 topics

Innovation & R&D1Product Launch1Demand1

Trends2 quarters

Questions per Quarter

Questions

Challenging

Companies Covered

Question History2 questions

INSMInsmed Incorporated2 quarters

2026 Q1

is it fair to assume that this will be reflective of sort of the Phase III doses? I guess really the question is, will patients have enough time to titrate up

Innovation & R&DView in transcript →

2025 Q3

what's been like the feedback among physicians and sort of the appetite among physicians to use this in maybe more moderate patients or even patients with only one recent sort of exacerbation?

Product LaunchDemandView in transcript →